HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kaopectate Prop 65

This article was originally published in The Tan Sheet

Executive Summary

San Francisco County Judge approves settlement between Pfizer, Attorney General Bill Lockyer in Prop 65 lawsuit regarding Kaopectateanti-diarrheal. Pfizer, which obtained the drug after acquiring Pharmacia, agrees to reformulate Kaopectate liquid with 80% less lead; caplets have not yet been reformulated. "The faster and more extensively Pharmacia removes lead from Kaopectate, the less it will pay in civil penalties," AG's office states June 26. Center for Environmental Health filed suit in 2001 (1"The Tan Sheet" March 26, 2001, p. 21). State AG joined in November 2001...

You may also be interested in...

Smoking Cessation Patch, Gum Prop 65 Warning Federally Preempted - Court

Requiring a special California Proposition 65 pregnancy warning on OTC nicotine-containing smoking cessation patches and gums would conflict with FDA requirements, a San Francisco state court judge has ruled.

Outlook 2023: Market Experts On Importance Of Value, Mental Health In A ‘World On Fire’

Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.

Keeping Track: Two Targeted Oncologics And A Novel SGLT-2 Inhibitor Clear US FDA

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts